Dynasil subsidiary Xcede Technologies said yesterday it inked collaborative development, licensing and supply agreements with Cook Medical‘s Biotech biz to aid in the development and regulatory approval of its resorbable hemostatic patch.
The hemostatic patch is being designed to control severe bleeding in surgical situations, and the company hopes to begin clinical trials of the patch some time in early 2017, Xcede said.
“We are excited to announce this collaboration with Cook Biotech. We believe that Cook’s experience and depth in the marketplace will provide a solid foundation for bringing our hemostatic patch into clinical development and on to regulatory approval and commercial sales,” Xcede CEO Linda Zuckerman said in a press release.
Rochester, Minn. and Seattle, Wash.-based Xcede was formed in 2013 following a technology transfer from Dynasil Corp subsidiary Dynasil Biomedical, the company said.
“Cook’s SIS matrix technology combined with Xcede’s adhesive technology provides an excellent foundation for Xcede’s first product and the basis for potential expansion to other products to be commercialized with Cook. We are excited to announce this collaboration with Xcede Technologies,” Cook Biotech GM Umesh Patel said in a prepared statement.